Navigation Links
Symposium Highlights Yale Study Indicating Role of AHCC(R) for Immune System Enhancement and as a Promising Cancer Preventative
Date:9/16/2008

Significant Research Presented at the AHCC International Research Symposium

PURCHASE, N.Y., Sept. 16 /PRNewswire/ -- The 16th International AHCC(R) (Active Hexose Correlated Compound) Symposium was held in Sapporo, Japan on July 26th and 27th. The Symposium hosted by the AHCC Research Association was attended by over 300 medical doctors and researchers from around the world that presented and discussed research studies completed with AHCC. Individuals attending this year's event included representatives from Harvard Medical School, Yale University School of Medicine and the M.D. Anderson Cancer Center.

Significant preliminary findings from a Yale School of Medicine clinical study were presented. Researchers at Yale, in collaboration with researchers in Japan, have confirmed that AHCC significantly enhances the immune system in a manner that may prove significant for healthy immune function and as a cancer preventative for older Americans.

Study participants were normal healthy individuals 50 years or older and were provided AHCC for 60 days. Scientists measured the production of two key cytokines -- Interferon (IFN-y) and Tumor Necrosis Factor (TNF-alpha) -- at the baseline, 30 days and 60 days. These two cytokines are believed to serve a major role in the body's natural method of preventing the formation and spread of abnormal and cancerous cells.

Yale researchers then measured the levels of these cytokines in the blood. Results demonstrated that the production of these cytokines by white blood cells increased within four weeks of taking the recommended dose of AHCC. The study also showed that the immune-enhancing effect of AHCC persisted for at least a month after stopping the daily dose. The results of this study not only confirmed the efficacy of the compound but also helped explain one of the mechanisms by which AHCC enhances the immune system.

The two keynote presentations from researchers in Japan focused on the value of AHCC in cancer therapy. Professor Emeritus Masuo Hosokawa of Hokkaido University gave an overview of the completed research on the effects of AHCC in reducing the side-effects of chemotherapy. The second keynote featured Professor Emeritus Yasuo Kamiyama of Kansai Medical University whose research investigated AHCC as a complementary therapy to pharmaceuticals in post-operative cancer patients along with cancer patients having additional complications.

A scientific review study soon to be published in the upcoming Nutritional Reviews Journal was presented by Dr. Barry Ritz of Drexel University's Department of Biotechnology. The paper gave an overview of the research studies -- published in peer-reviewed journals -- on the positive effect of AHCC on the influenza virus, the avian "bird flu" virus (H5N1), the West Nile virus, the Methicillin-Resistant Staphylococcus aureus (MRSA), the Klebsiella pnuemoniae and the Candida albicans viruses. It was reported that supplementation with AHCC modulated immunity and delivered positive results in response to acute infections.

"AHCC continues to demonstrate its essential role for healthy immune function," said Fred Pescatore, M.D., M.P.H., of the Center for Integrative and Complementary Medicine, and medical director for the U.S. AHCC Research Association in response to the research presented at this year's Symposium.

AHCC has been the subject of over 80 research studies worldwide including studies completed at Harvard University's Faulkner Hospital, Yale University and Columbia University Medical Center. Research has demonstrated that AHCC enhances the immune system by increasing the activity of white blood cells.

What is AHCC (Active Hexose Correlated Compound)?

AHCC is derived from the hybridization of several subspecies of medicinal mushroom, cultivated in Japan and then produced from a specialized manufacturing process. AHCC is the leading immune-enhancing supplement in Japan and is utilized by over 700 hospitals and healthcare facilities worldwide as a standard preventative supplement for incoming patients to help reduce the risk of hospital infections as well as supporting the body's fight against the formation of abnormal cells.*

AHCC is manufactured by Amino Up Chemical Company in Sapporo, Japan and is distributed in the United States by Maypro Industries. Maypro sells AHCC to a number of leading supplement companies including Quality of Life Laboratories, a subsidiary of Maypro.

The AHCC Research Association was founded in 1986 to promote further study. Each year since 1994, over 300 medical doctors and researchers have gathered in Sapporo, Japan for the AHCC Research Association Symposium to share and discuss the latest developments.

To learn more about AHCC, visit the AHCC Research Association Web site at http://www.ahccresearch.com

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or mitigate disease.


'/>"/>
SOURCE AHCC Research Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Electronic Brachytherapy a Viable Option for Early Stage Breast Cancer, According to Study Presented at ASCO Breast Cancer Symposium
2. International Symposium on Malignant Mesothelioma 2008
3. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
4. Access Pharmaceuticals Presents New Data on the Companys Cobalamin(TM) Technology at an International Polymer Therapeutics Symposium
5. Stereotaxis Market Leadership Reinforced in Core Curriculum and Symposium Presentations at Heart Rhythm 2008
6. Data from Randomized Pilot Study, Real-World Use of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) to be Presented in Symposium at EuroPCR 2008
7. Clinical Impact of OrbusNeichs Genous(TM) Bio-engineered R stent(TM) is Subject of Symposium at 16th Annual Scientific Congress of Hong Kong College of Cardiology
8. Preliminary PI-88 Phase 2 Prostate Cancer Results to be Presented at the American Society for Clinical Oncology (ASCO) 2008 Genitourinary Cancer Symposium
9. Clinical Experience With Peregrines Anti-Cancer Agent Bavituximab Presented at Leading Symposium on Anti-Angiogenic Agents
10. Over 30 New Studies of Oral Xeloda(R) Featured at the 2008 Gastrointestinal Cancers Symposium
11. US Oncology Research Network Presents Clinical Studies at San Antonio Breast Cancer Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 ... providing high-quality and cost-effective drug development and ... pharmaceutical and biotechnology industry, announced today the ... ShangPharma will be consolidating the Contract ... (CMO) under Shanghai ChemPartner. These entities include ...
(Date:3/24/2017)... 24, 2017 Research and Markets has announced the ... report to their offering. ... The IPF pipeline is very strong with a total of 97 ... Inc., Biogen and Sanofi are involved in the development of the IPF ... is in Phase III stage, 15 are in Phase II stage, 12 ...
(Date:3/24/2017)... India , March 24, 2017 ... of the industry including definitions, classifications, applications and industry ... the international market including development history, competitive landscape analysis, ... ... Ampoules industry spread across 105 pages providing 10 company ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... 2017 , ... “The Communion of Saints: A Pastor’s Potpourri ... congregations across the United States. “The Communion of Saints” is the creation ... served congregations in seven states throughout his long career of devotion to the ...
(Date:3/23/2017)... Houston, Texas (PRWEB) , ... March 23, 2017 , ... ... their 3rd location in the greater Houston Area. The new location is located at ... St. Luke’s Hospital in Springwoods Village. This newest location will provide patients living in ...
(Date:3/23/2017)... ... 2017 , ... The IoT (Internet of Things) is revolutionizing the way the ... on businesses and individual consumers alike. Laboratories can maximize their profit margin by ... from $4 trillion to $11 trillion dollars by the year 2025. McKinsey expects the ...
(Date:3/23/2017)... (PRWEB) , ... March 23, 2017 , ... March is ... that pack a punch when it comes to maintaining good health. Every day, two ... minutes, your kidneys filter every drop of your blood, eliminating waste, regulating fluid levels ...
(Date:3/23/2017)... PA (PRWEB) , ... March 23, 2017 , ... ... comprehensive educational training program owned and organized by HMP Communications Holdings, LLC, today ... program for physicians within its nationwide network of wound centers interested in becoming ...
Breaking Medicine News(10 mins):